tbuckley/cabot-search huggingface dataset:
‘Beware of the deep’: the deep posterior compartment in complex/chronic leg pain
Authors: Mark R Hutchinson
Journal: British Journal of Sports Medicine (2013)

Michael Winkes and his colleagues1 do an admirable job of performing a systematic review on a controversial topic for those of us who care for athletes with leg pain. Like these authors, most of us have come to the frustrating realisation that patients with deep posterior exertional compartment syndromes do less well than those with the more classic anterior or lateral exertional compartment syndrome.

The authors validate the clinical experience of many through a comprehensive, systematic review. Through this review, the authors also expose …
Individual Characteristics Associated with PBDE Levels in U.S. Human Milk Samples
Authors: Julie L. Daniels, I-Jen Pan, Richard Jones, Sarah Anderson, Donald G. Patterson, Larry L. Needham, Andreas Sjödin
Journal: Environmental Health Perspectives (2009)

Reported polybrominated diphenyl ether (PBDE) concentrations in human samples in the United States have been higher than in Europe and Asia. Little is known about factors that contribute to individual variability in body burden.
Insulinoma producing progressive neurological deterioration over 30 years.
Authors: J A Snook, R vanderStar, R O Weller
Journal: BMJ (1986)

Primary biliary cirrhosis after benoxaprofenBenoxaprofen was withdrawn from use in 1982 because of reports of it causing fatal, cholestatic jaundice.We report three cases of primary biliary cirrhosis after benoxaprofen, an association not previously recognised. Case reports CASE 1A 67 year old woman received benoxaprofen 600 mg/day for three months in 1981 for sciatica.A further course was given between April and June 1982, during which she developed a photosensitive rash and brittle nails.Shortly afterwards she was found to have raised serum alkaline phosphatase activity.From November 1982 she noticed increasing skin pigmentation, followed eight months later by jaundice and hepatomegaly.Follow up confirmed persistently abnormal liver function with a positive result on antimitochondrial antibody testing and liver histology compatible with primary biliary cirrhosis (table).CASE 2A 57 year old woman with rheumatoid arthritis received benoxaprofen 600 mg/day from December 1980 to June 1982, when she developed a generalised, pruritic rash that cleared when the drug was stopped, although pruritus persisted.In March 1983 she was admitted to hospital with deep jaundice, loss of weight and hepatosplenomegaly.The results of an antimitochondrial antibody test were positive; liver function deteriorated until her death 28 months after initial diagnosis. CASE 3A 62 year old woman with primary hyperparathyroidism was admitted to hospital in January 1983 with lethargy, nausea, and vomiting.She had received benoxaprofen 600 mg/day from April 1981 to March 1982, when she developed a pruritic rash; two months before this her liver function tests had yielded normal results.FoLlow up over 30 months confirmed persistently raised serum alkaline phosphatase activity despite normal concentrations ofserum calcium and positive results on antimitochondrial antibody testing.
A Pilot Study of [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non–Small-Cell Lung Cancer
Authors: Feng-Ming Spring Kong, Kirk A. Frey, Leslie E. Quint, Randall K. Ten Haken, James A. Hayman, Marc Kessler, Indrin J. Chetty, Daniel Normolle, Avraham Eisbruch, Theodore S. Lawrence
Journal: Journal of Clinical Oncology (2007)

Purpose To study whether changes of [ 18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) during treatment correlate with post-treatment responses in tumor and normal lung in patients with non–small-cell lung cancer (NSCLC). Patients and Methods Patients with stage I to III NSCLC requiring a definitive dose of fractionated radiation therapy (RT) were eligible. FDG-PET/computed tomography scans were acquired before, during, and after RT. Tumor and lung metabolic responses were assessed qualitatively by physicians and quantitatively by normalized peak FDG activity (the ratio of the maximum FDG activity divided by the mean of the aortic arch background). Results The study reached the goal of recruiting 15 patients between February 2004 and August 2005. Of these, 11 patients had partial metabolic response, two patients had complete metabolic response, and two patients had stable disease at approximately 45 Gy during RT. The mean peak tumor FDG activity was 5.2 (95% CI, 4.0 to 6.4), 2.5 (95% CI, 2.0 to 3.0), and 1.7 (95% CI, 1.3 to 2.0) on pre-, during, and post-RT scans, respectively. None of the patients had appreciable changes in the lung during RT. The peak FDG activity of the lung was 0.47 (95% CI, 0.36 to 0.59), 0.52 (95% CI, 0.40 to 0.64), and 1.29 (95% CI, 0.82 to 1.76), on pre-, during-, and post-RT scans, respectively. The qualitative response during RT correlated with the overall response post-RT (P = .03); the peak tumor FDG activity during RT correlated with those 3 months post-RT (R 2 = 0.7; P &lt; .001). Conclusion This pilot study suggests a significant correlation in tumor metabolic response and no association in lung FDG activity between during RT scans and 3 months post-RT scans in patients with NSCLC. Additional study with a large number of patients is needed to validate these findings.
HIGH PREVALENCE AND CLINICAL SIGNIFICANCE OF HYPERTENSIVE RESPONSE TO DOBUTAMINE STRESS IN END STAGE RENAL DISEASE PATIENTS UNDERGOING EVALUATION FOR RENAL TRANSPLANTATION
Authors: Waqas Aftab, Shuja Rasool, Padmini Varadarajan, Ali Motabar, Juliana Gazallo, Arputharaj Kore, Michel DeVera, Ramdas Pai
Journal: Journal of the American College of Cardiology (2012)
582 High response rates with peginter-feron α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in Japanese non-responders or relapsers to conventional interferon
Authors: N. Izumi, S. Iino, T. Okuno, M. Omata, K. Kiyosawa, H. Kumada, N. Hayashi, G. Yamada, T. Sakai
Journal: Journal of Hepatology (2006)
Deferred Consent
Authors: Norman S. Abramson
Journal: JAMA (1986)

Methodological constraints inherent in the rapidly growing field of resuscitation research have created an apparent conflict with newly promulgated federal regulations, especially those concerning informed consent requirements. We propose that two new concepts be applied to resuscitation research to satisfy the current federal regulations governing biomedical research. The first of these concepts is "minimal differential risk," ie, in resuscitation medicine, the difference between the risk of an undesirable outcome when standard, commonly accepted therapy may be used and the risk of an undesirable outcome with experimental therapy is minimal. The second concept is "deferred consent," ie, obtaining consent to<i>continue</i>with an experimental therapy after administration of that therapy has already begun. We believe that the emergency exception to informed consent applies to resuscitation research. Recognition of the applicability of these concepts to resuscitation research should allow compliance with federal and state regulations that otherwise might inhibit or preclude such research endeavors. (<i>JAMA</i>1986;255:2466-2471)
Phospholamban Gene Dosage Effects in the Mammalian Heart
Authors: Wusheng Luo, Beata M. Wolska, Ingrid L. Grupp, Judy M. Harrer, Kobra Haghighi, Donald G. Ferguson, Jay P. Slack, Gunter Grupp, Thomas Doetschman, R. John Solaro, Evangelia G. Kranias
Journal: Circulation Research (1996)

Phospholamban ablation has been shown to result in significant increases in cardiac contractile parameters and loss of beta-adrenergic stimulation. To determine whether partial reduction in phospholamban levels is also associated with enhancement of cardiac performance and to further examine the sensitivity of the contractile system to alterations in phospholamban levels, hearts from wild-type, phospholamban-heterozygous, and phospholamban-deficient mice were studied in parallel at the subcellular, cellular, and organ levels. The phospholamban-heterozygous mice expressed reduced cardiac phospholamban mRNA and protein levels (40 +/- 5%) compared with wild type mice. The reduced phospholamban levels were associated with significant decreases in the EC50 of the sarcoplasmic reticulum Ca2+ pump for CA2+ and increases in the contractile parameters of isolated myocytes and beating hearts. The relative phospholamban levels among wild-type, phospholamban-heterozygous, and phospholamban-deficient mouse hearts correlated well with the (1) EC50 of the Ca(2+)-ATPase for Ca2+ in sarcoplasmic reticulum, (2) rates of relaxation and contraction in isolated cardiac myocytes, and (3) rates of relaxation and intact beating hearts. These findings suggest that physiological and pathological changes in the levels of phospholamban will result in parallel changes in sarcoplasmic reticulum function and cardiac contraction.
The Status and Future of Small Maternity Services in Iowa
Authors: Herman A. Hein
Journal: JAMA (1986)

Small Iowa community hospitals (fewer than 500 deliveries annually) are currently the site of approximately 37% of hospital births in the state. Many of these facilities face severe financial constraints aggravated by reduced Medicare payments and diagnosis-related group payment mechanisms. The quality and quantity of services provided by small hospitals are illustrated by birth and mortality data for the period that spans the development of Iowa's regionalized perinatal care system. Small hospitals appear to compare very favorably when matched with their larger level I counterparts with regard to neonatal mortality rates, incidence of births of very-low-birth-weight neonates, survival of very-low-birth-weight neonates, occurrence of neonatal deaths relative to the total birth population, and incidence of neonatal morbidities. Because these hospitals provide valuable services in Iowa's perinatal care system, their closure may seriously compromise perinatal health care for rural lowans. (<i>JAMA</i>1986;255:1899-1903)
Robot-assisted Radical Cystectomy and Urinary Diversion: Technical Recommendations from the Pasadena Consensus Panel
Authors: Kevin G. Chan, Khurshid Guru, Peter Wiklund, James Catto, Bertram Yuh, Giacomo Novara, Declan G. Murphy, Tareq Al-Tartir, Justin W. Collins, Ali Zhumkhawala, Timothy G. Wilson
Journal: European Urology (2015)
THE CHOLESTEROL FUNCTION OF THE GALL BLADDER
Authors: Robert Elman, J. B. Taussig
Journal: The Journal of Experimental Medicine (1931)

Cholesterol determinations of gall bladder and hepatic bile obtained from the same source reveal a greater concentration in the former even after the inspissating effect of the gall bladder is allowed for. This evidence together with that from other experiments indicates that the gall bladder has the power to excrete cholesterol into its lumen. There is evidence also that infection may accelerate this excretion. An hypothesis is presented to explain the precipitation of cholesterol in the bile, and the bearing of these findings on the pathogenesis of cholesterol stones is briefly discussed.
Hemodialysis in the Home
Authors: J. P. Merrill, E. Schupak, E. Cameron, C. L. Hampers
Journal: JAMA (1964)

IN RECENT YEARS it has been adequately proven that for some patients with chronic renal failure in whom conservative treatment is inadequate, useful existence may be maintained for significant periods of time by the use of a regularly scheduled program of hemodialysis with the artificial kidney. Although the number of patients so treated is small, the preponderance of evidence indicates that in the hands of an experienced team hemodialysis may be considered a successful, though temporary, means of treating chronic uremia.<sup>1</sup>The demonstration of this possibility raises important questions about the need for its wider application. It is estimated that in the US, 2,000 patients per year who die of chronic renal failure might survive with this form of treatment.<sup>2</sup>The cost of maintaining eight patients in this fashion has been estimated at $10,000 per patient per year<sup>2</sup>by the chronic dialysis center in Seattle. This figure
Salsalate and Minimal-Change Nephrotic Syndrome
Authors: MARTI VALLÈ
Journal: Annals of Internal Medicine (1987)

Letters and Corrections1 July 1987Salsalate and Minimal-Change Nephrotic SyndromeMARTI VALLÈ, M.D., JOSé L. TOVAR, M.D.MARTI VALLÈ, M.D.Search for more papers by this author, JOSé L. TOVAR, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-1-116_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Acute interstitial nephritis and minimalchange glomerulopathy has been reported as adverse reactions with most of the nonsteroidal antiinflammatory drugs (1-3), although isolated nephrotic syndrome secondary to minimalchange glomerulopathy has been infrequently attributed to these kinds of drugs (4). However, the syndrome has never been associated with the nonsteroidal antiinflammatory agent, salsalate, as it is herein reported.A 76-year-old man was hospitalized with a clinical and biologic nephrotic syndrome. Major biochemical abnormalities included a serum albumin level of 1.63 gm/dL and proteinuria, 11 g/24-h urine sample. Moderate renal insufficiency with a serum creatinine level of 2.6 mg/dL was...References1. CLIVESTOFF DJ. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563-72. CrossrefMedlineGoogle Scholar2. GARELLAMATARESSE SR. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 1984;63:165-81. CrossrefMedlineGoogle Scholar3. POIRIER T. Reversible renal failure associated with Ibuprofen: case report and review of the literature. Drug Intell Clin Pharm. 1984;18:27-32. CrossrefMedlineGoogle Scholar4. LOMVARDIASPINNWADHWAKOSHYHELLER SVMKM. Nephrotic syndrome associated with sulindac [Letter]. N Engl J Med. 1981;304:424. CrossrefMedlineGoogle Scholar5. KIMBERLYSHERMANMOURADIANLOCKSHIN RRJM. Apparent acute renal failure associated with therapeutic aspirin and Ibuprofen administration. Arthritis Rheum. 1979;22:281-5. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Hospital General Vall d'Hebron Catalunya, Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGlomerular, tubular and interstitial nephritis associated with non‐steroidal antiinflammatory drugs. Evidence of a common mechanismAcute Renal Failure Following Binge Drinking and Nonsteroidal Antiinflammatory DrugsAcute Interstitial Nephritis with Glomerulopathy Due to Nonsteroidal Anti-Inflammatory Agents: A Review of Its Clinical Spectrum and Effects of Steroid TherapyRecurrence and specificity of nephrotic syndrome due to tolmetinAntipyretic analgesics 1 July 1987Volume 107, Issue 1Page: 116-116KeywordsAdverse reactionsBiologicsCreatinineNSAIDsNephritisProteinuriaSerum albuminUrine ePublished: 1 December 2008 Issue Published: 1 July 1987 PDF downloadLoading ...
Optimal Waist Circumference Measurement Site for Assessing the Metabolic Syndrome
Authors: Yumi Matsushita, Kentaro Tomita, Tetsuji Yokoyama, Tetsuya Mizoue
Journal: Diabetes Care (2009)

In the assessment of diagnostic criteria for the metabolic syndrome, much work, including ours (1), has been done to identify an optimal cutoff value for waist circumference, i.e., one that best predicts the clustering of metabolic risk factors. By contrast, little attention has been paid to the waist circumference site to be measured and its impact on the prevalence of metabolic syndrome, although definitions of waist circumference measurement vary among guidelines for the syndrome. This point should be clarified given the large variations in waist circumference according to the site measured (2).

We measured waist circumference at various sites in 1,140 Japanese subjects (969 men …
Social Anxiety Disorder
Authors: Franklin R Schneier
Journal: New England Journal of Medicine (2006)

A 28-year-old man reports feeling anxious and self-conscious around people in school, work, and social situations since his early teens. He appears shy and, on questioning, describes avoidance of speaking up in work meetings, attending social gatherings, and dating. He desperately wants to be more socially active but fears he will appear nervous and embarrass himself. How should he be evaluated and treated?
Isoniazid Prophylaxis-Reply
Authors: F. Marc LaForce
Journal: JAMA (1987)

<h3>In Reply.—</h3> Drs Bass and Snider are correct. Isoniazid prophylaxis is recommended for all infected persons under 35 years of age and for infected persons over 35 years of age with special risk factors. The American Thoracic Society and the Centers for Disease Control statement<sup>1</sup>should be consulted for further details. I apologize for the error and thank Drs Bass and Snider for bringing it to my attention.
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Authors: Helle J. Jacobsen, Thomas T. Poulsen, Anna Dahlman, Ida Kjær, Klaus Koefoed, Jette W. Sen, Dietmar Weilguny, Bolette Bjerregaard, Christina R. Andersen, Ivan D. Horak, Mikkel W. Pedersen, Michael Kragh, Johan Lantto
Journal: Clinical Cancer Research (2015)

Accumulating evidence indicates a high degree of plasticity and compensatory signaling within the human epidermal growth factor receptor (HER) family, leading to resistance upon therapeutic intervention with HER family members.We have generated Pan-HER, a mixture of six antibodies targeting each of the HER family members EGFR, HER2, and HER3 with synergistic pairs of antibodies, which simultaneously remove all three targets, thereby preventing compensatory tumor promoting mechanisms within the HER family. Pan-HER induces potent growth inhibition in a range of cancer cell lines and xenograft models, including cell lines with acquired resistance to therapeutic antibodies. Pan-HER is also highly efficacious in the presence of HER family ligands, indicating that it is capable of overcoming acquired resistance due to increased ligand production. All three target specificities contribute to the enhanced efficacy, demonstrating a distinct benefit of combined HER family targeting when compared with single-receptor targeting.Our data show that simultaneous targeting of three receptors provides broader efficacy than targeting a single receptor or any combination of two receptors in the HER family, especially in the presence of HER family ligands. Pan-HER represents a novel strategy to deal with primary and acquired resistance due to tumor heterogeneity and plasticity in terms of HER family dependency and as such may be a viable alternative in the clinic.
Determining Risks to Health: Federal Policy and Practice
Authors: Harold J. Magnuson
Journal: JAMA (1986)

This book is based on a 1985 report to the Secretary of the Department of Health and Human Services, by an intramural task force instructed to review the department's activities in health risk assessment and management. The report is in the book appendix. Risk assessment is here defined as "the qualitative or quantitative estimation of adverse effects from exposure to specific health hazards or<i>from the absence of beneficial effect</i>" (italics added). The component units of the department completed a questionnaire describing their activities in the defined area. Since the Department of Health and Human Services includes the Alcohol, Drug Abuse, and Mental Health Administration, the Agency for Toxic Substances Disease Registry, the Centers for Disease Control, the Food and Drug Administration, the National Institutes of Health, and the Office of the Assistant Secretary for Health, the report covers a significant portion, but not all, of the federal government's health
Printer's Deviltry
Authors: Franz J. Ingelfinger
Journal: New England Journal of Medicine (1976)

Editors receive criticisms from many sources, and their families are no exception. A month ago, my daughter-in-law, who had been invited by the Massachusetts General Hospital to discuss a clinicopathological conference, complained that her first name on the Journal's front cover Table of Contents looked like Fulie rather than Julie. In fact, she said, the Journal's upper-case (capital) italic J had looked like F ever since the issue of February 26, 1976. Although no one on the Journal staff had noticed, an investigation turned out that she was right: on that date the printer had introduced a new italic type . . .
Is ventilatory efficiency (VE/VCO<sub>2</sub> slope) associated with right ventricular oxidative metabolism in patients with congestive heart failure?
Authors: Heikki Ukkonen, Ian G. Burwash, William Dafoe, Robert A. de Kemp, Haissam Haddad, Keiichiro Yoshinaga, Ross A. Davies, Edward K. Gannon, Jean N. DaSilva, Rob S.B. Beanlands
Journal: European Journal of Heart Failure (2008)
Liverpool care pathway offers no added benefits over usual care for dying patients, finds study
Authors: Z. Kmietowicz
Journal: BMJ (2013)

The Liverpool care pathway provides the same quality of care as that usually provided to cancer patients who are dying in hospital, a study has found.1

The authors say that because care under the pathway is no better than standard care any initiative to replace the pathway in England should be “grounded in scientific evidence” and tested in controlled trials before it is implemented.

In a commentary on the study, David Currow, from Flinders University in Adelaide, Australia and Amy Abernethy, from Duke Clinical Research Institute in the United States, say, “Across healthcare there is a need to improve care for people who are dying, which has led to widespread uptake of the …
Cutting Into Cholesterol
Authors: Patrick McBride
Journal: JAMA (1988)

<h3>To the Editor.—</h3> The analysis of cost-effective alternatives for treating hypercholesterolemia by Drs Kinosian and Eisenberg<sup>1</sup>published in the April 15 issue of<i>JAMA</i>provides important information for discussion of the treatment of risk factors for coronary heart disease. Updates of several studies mentioned in their article provide additional information relevant to the analysis of their article. The authors used a dosage of oat bran of 90 g/d to predict a 13% reduction in cholesterol level during the initial year and an overall reduction of 8.7% over seven years. A recent study published by Anderson<sup>2</sup>indicates that 50 g of oat bran was as effective as 100 g/d and produced overall cholesterol level reductions of 19.8%. The lower oat bran dosage could reduce the authors' cost estimates for oat bran by 44%, to a cost per year of life saved of $9968, making this treatment even more cost-effective.